How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

808 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Antioxidative, antifungal, cytotoxic and antineurodegenerative activity of selected Trametes species from Serbia. Full Text available with Trip Pro

, and that cervix adenocarcinoma cells were the most sensitive to the extracts and commercial cytostatics. T. versicolor mycelium extract was the most effective inhibitor of acetylcholinesterase activity but double weaker than galantamine, and T. gibbosa mycelium extract was significantly better inhibitor of tyrosinase activity than kojic acid for 40.9%. Chemical analysis indicated strong synergistic action of triterpenes, sugars and polyphenols in applied assays. The results suggest that tested Trametes

2018 PLoS ONE

162. Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study. Full Text available with Trip Pro

inhibitor (ChEI) drug therapy for dementia management.All community-dwelling Ontario residents aged 66 years and older with dementia and newly dispensed an oral ChEI drug (donepezil, galantamine, or rivastigmine) between April 1, 2010 and June 30, 2016 were included.The association between physician sex and the initiation of a lower than recommended-dose ChEI was examined using generalized linear mixed regression models, adjusting for patient and physician characteristics. Data were stratified

2018 PLoS ONE

165. Management of schizophrenia

of augmentation of antipsychotics with acetylcholinesterase inhibitors identified 13 double blind studies (six with donepezil, three with galantamine and four with rivastigmine,). Significant improvement was found for various aspects of memory (by an average of 28%, in three studies, in 146 participants, 95% CI 0.06 to 0.50, p=0.014) and on the trail making test part A (by 69%, in four studies, in 93 participants, 95% CI -1.14 to -0.23, p=0.003). 125 B Acetylcholinesterase inhibitors may be considered

2013 SIGN

166. Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial. (Abstract)

Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial. To treat patients with bipolar disorders (BPD) during the acute phase, the standard procedure is to administer lithium or sodium valproate. To further optimize treatment, acetylcholinesterase inhibitors such as donepezil and galantamine have gained increased interest, though with conflicting

2019 Neuropsychobiology Controlled trial quality: uncertain

167. Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease. Full Text available with Trip Pro

Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease. Disruption of cholinergic and serotonergic neurotransmitter systems is associated with cognitive, emotional and behavioural symptoms of Alzheimer's disease (AD). To investigate the responsiveness of these systems in AD we measured the effects of a single-dose of the selective serotonin reuptake inhibitor citalopram and acetylcholinesterase inhibitor galantamine in 12 patients with AD (...) coming from cerebrospinal fluid and white matter as covariates at the subject level, and baseline and heart rate measurements as confound regressors in the higher-level analysis (at p < 0.05, corrected). A galantamine induced difference between groups was observed for the cerebellar network. Connectivity within the cerebellar network and between this network and the thalamus decreased after galantamine vs. placebo in AD patients, but not in controls. For citalopram, voxelwise network connectivity did

2019 NeuroImage Controlled trial quality: uncertain

168. Leaf extracts from Dendropanax morbifera Léveille mitigate mercury-induced reduction of spatial memory, as well as cell proliferation, and neuroblast differentiation in rat dentate gyrus. Full Text available with Trip Pro

and differentiated neuroblasts.Dimethylmercury (5 μg/kg) and galantamine (5 mg/kg) was administered intraperitoneally and/or DML (100 mg/kg) was orally to 7-week-old rats every day for 36 days. One hour after the treatment, novel object recognition test was examined. In addition, spatial probe tests were conducted on the 6th day after 5 days of continuous training in the Morris swim maze. Thereafter, the rats were euthanized for immunohistochemical staining analysis with Ki67 and doublecortin and measurement (...) the administration of DML or galantamine significantly increased the number of crossings than did dimethylmercury treatment alone. Proliferating cells and differentiated neuroblasts, assessed by Ki67 and doublecortin immunohistochemical staining was significantly decreased in the dimethylmercury treated group versus controls. Supplementation with DML or galantamine significantly increased the number of proliferating cells and differentiated neuroblasts in the dentate gyrus. In addition, treatment

2019 BMC Complementary and Alternative Medicine

169. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis. (Abstract)

inconclusive.A network meta-analysis was conducted to evaluate the therapeutic benefits and tolerability of EGb761, three ChEIs (donepezil, galantamine, and rivastigmine), and memantine in mild-to-moderate AD patients.Electronic databases were searched through 30 June 2017. We included randomized double-blinded trials with a minimum treatment duration of 22 weeks for EGb761 240 mg/day and 12 weeks for ChEIs or memantine. The study patients included AD or probable AD patients without other types of dementia (...) showed no therapeutic benefits in all study outcomes. For cognition, all ChEIs were significantly better than placebo (SMD from - 0.52 to - 0.26), and galantamine was better than rivastigmine in the oral and patch forms, EGb761, and memantine (SMD [95% confidence interval (CI)]: - 0.22 [- 0.40 to - 0.05]; - 0.26 [- 0.45 to - 0.07]; - 0.34 [- 0.56 to -  0.12]; and - 0.42 [- 0.71 to - 0.13], respectively). Compared to placebo, galantamine, the rivastigmine patch, and oral rivastigmine provided modest

2019 Drugs & Aging

170. Pharmacological Management of Dementia with Lewy Bodies. Full Text available with Trip Pro

shown to be effective in managing the cognitive and behavioral symptoms of DLB: rivastigmine, galantamine and donepezil. Memantine is able to improve clinical global impression of change in those with mild to moderate DLB. Levodopa can treat the parkinsonism of some DLB patients, but the dose is often limited due to the fact that it can cause agitation or worsening of visual hallucinations. A recent phase 2 clinical trial showed the benefit of zonisamide when it is added as an adjunct to levodopa

2019 Drugs & Aging

172. Balaxur (memantine hydrochloride / donepezil hydrochloride)

, noradrenergic, and glutamatergic neurons. The incidence of Alzheimer's disease is approximately 10% in the population over 65 years of age and increases progressively with age to reach about 30% by the end of a century of life. Currently, available pharmacological therapies are the AChEI (e.g donepezil, galantamine and rivastigmine) and memantine that are acting on AD with different mechanisms of action (MoA) as explained above. Balaxur is a fixed-dose combination (FDC) product of memantine (20 mg

2013 European Medicines Agency - EPARs

174. Acrescent (memantine hydrochloride / donepezil hydrochloride)

donepezil, galantamine and rivastigmine) and memantine that are acting on AD with different mechanisms of action (MoA) as explained above. Acrescent is a fixed-dose combination (FDC) product of memantine (20 mg) and donepezil (10 mg), presented as film-coated tablets (memantine 20 mg/donepezil 10 mg). Acrescent has been developed as a substitution indication i.e. in patients adequately controlled with the individual products given concurrently at the same dose level as in the combination

2013 European Medicines Agency - EPARs

175. Generalized anxiety disorder

(such as haloperidol), antihistamines (such as mizolastine), and antiretrovirals (such as ritonavir, saquinavir, and lopinavir). Paroxetine: Avoid concurrent use with tamoxifen. Paroxetine is a potent inhibitor of the liver enzyme CYP2D6 and may reduce the plasma concentration of tamoxifen, leading to reduced efficacy. Paroxetine may increase the plasma concentrations of aripiprazole, clozapine, darifenacin, galantamine, methadone, metoprolol, pitolisant, procyclidine, ranolazine, risperidone and vortioxetine

2017 NICE Clinical Knowledge Summaries

176. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease

valid, but the clinical evidence was weak. Further studies are needed to support the authors’ findings. Type of economic evaluation Cost-utility analysis Study objective This study assessed the cost-effectiveness of adding memantine to the usual cholinesterase inhibitor treatment for patients with Alzheimer's disease. Interventions A cholinesterase inhibitor, donepezil, rivastigmine, or galantamine, was compared against memantine plus a cholinesterase inhibitor. Location/setting Canada/community

2012 NHS Economic Evaluation Database.

177. Memantine in Combination with Cholinesterase Inhibitors for Alzheimer?s Disease: Clinical Effectiveness and Safety

://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823571 PubMed: PM19204022 Memantine in Combination with Cholinesterase Inhibitors for Alzheimer’s Disease 5 PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: 1-866-898-8439 www.cadth.ca Memantine in Combination with Cholinesterase Inhibitors for Alzheimer’s Disease 6 APPENDIX – FURTHER INFORMATION: Guidelines and Consensus Statements 8. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease: review of NICE technology

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

178. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Full Text available with Trip Pro

, in the Netherlands. CRD commentary Interventions: Memantine was appropriately compared with no pharmacological treatment. The authors stated that galantamine was another medical treatment for Alzheimer’s disease, but was not directly comparable. Effectiveness/benefits: The clinical data appear to have been from appropriate sources. The treatment effect was from a pooled analysis of clinical trials which should have ensured high internal validity. Other data were adjusted for the Netherlands, using a large local

2012 NHS Economic Evaluation Database.

179. Therapeutic interventions for aphasia initiated more than six months post stroke: a review of the evidence Full Text available with Trip Pro

, donepezil, memantine and galantamine were found to be effective in one RCT each. However, two RCTs demonstrated that bromocriptine was not effective. Three RCTs assessed brain stimulation techniques and found that both repetitive transcranial magnetic stimulation (rTMS) and anodal transcranial direct current stimulation (tDCS) improved naming abilities and lexical production. Two RCTs demonstrated that constraint-induced aphasia therapy was effective. Authors' conclusions There was evidence to support

2012 DARE.

180. Open-label, PK and Safety Study in Mild-to-moderate Alzheimer's Disease Patients

at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-h) nursing care General health status acceptable for participation in the study Fluency (oral and written) in English or Spanish If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose for at least 3 months (90 days) before screening and with continuous dosing for at least 3 months. If receiving donepezil, receiving any dose lower than 23 mg once daily. The patient

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>